Solid Biosciences · 23 hours ago
Senior Director, Discovery & Translational Development
Boston, MA
Full-time
Onsite
Director/Executive
$260K/yr - $305K/yr
10+ years expSolid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases. The Senior Director, Discovery and Translational Development will be a senior scientific and operational leader responsible for building and advancing Solid’s early pipeline and providing scientific leadership for key development programs.
BiotechnologyGeneticsHealth CareMedical
Responsibilities
Lead the development and progression of early pipeline programs, from target identification through translational strategy definition and program readiness
Serve as scientific leader for a designated lead program, ensuring alignment of discovery, translational, and development strategies
Contribute to portfolio strategy and prioritization, including risk assessment, scenario planning, and definition of key decision points
Develop and deliver clear, concise, and decision-enabling scientific narratives to the executive team and governance forums
Provide oversight of discovery, translational, and biomarker assay strategy supporting early and advancing programs
Ensure assays are fit-for-purpose, robust, and scalable, with a clear line of sight to clinical and regulatory needs
Guide the development and qualification of assays spanning in vitro, in vivo, and translational biofluid and tissue-based endpoints
Qualification
Required
PhD, MD, or equivalent advanced degree in a relevant scientific discipline
10+ years of industry experience in discovery and/or translational research within biotech or pharmaceutical settings
Demonstrated experience in genomic medicines, with strong preference for AAV-based gene therapy
Proven ability to lead programs and teams across early discovery through IND-enabling development
Strong experience operating in cross-functional, matrixed environments
Exceptional ability to communicate complex science clearly and succinctly, particularly to senior and executive stakeholders
Preferred
Experience in genetic cardiomyopathies, cardiovascular biology, or related rare genetic diseases
Prior involvement in regulatory interactions and IND-supporting activities
Experience contributing to portfolio strategy and executive-level governance discussions
Comfort working in a fast-paced, evolving organization with multiple priorities
Benefits
Competitive Health and Dental programs with flexible plan offerings, including FSA and HSA programs
401(k) program participation with competitive company matched contributions
Eligibility to participate in Solid’s Employee Stock Purchase Plan
Mobile phone subsidy for eligible employees
Tuition Reimbursement
Vision Coverage
Life Insurance
Voluntary Pet Insurance
Employee Discount Program on Travel, Entertainment, and Services
Employee Assistance Programs
Daily Subsidized Lunch Delivery (onsite @ Hood Park)
Free Onsite Full-Service Gym (onsite @ Hood Park)
Employee Parking (onsite @ Hood Park)
12 Observed Holidays and a winter shut down
15-day PTO Policy and a 40-hour rollover YoY
40-hour Sick Policy
8 Hour Floating Holiday
Company
Solid Biosciences
Solid Biosciences is a life science company that conducts research for the treatment of Duchenne muscular dystrophy.
51-200 employees
H1B Sponsorship
Solid Biosciences has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (6)
2024 (3)
2023 (2)
2022 (4)
2021 (2)
2020 (1)
Funding
Current Stage
Public CompanyTotal Funding
$810.3MKey Investors
Ultragenyx PharmaceuticalPerceptive AdvisorsJP Morgan
2025-02-18Post Ipo Equity· $200M
2024-01-08Post Ipo Equity· $109M
2022-09-30Post Ipo Equity· $75M
Leadership Team
Alexander Cumbo
CEO and President
Kevin Tan
Chief Financial Officer
Recent News
Pharmaceutical Technology
2026-01-16
Company data provided by crunchbase